Pulnovo Medical, a Hong Kong-based globally pioneer in medical units for pulmonary hypertension (PH) and coronary heart failure (HF), acquired new funding from EQT Group, alongside continued assist from Qiming Enterprise Companions.
The quantity of the deal was not disclosed.
This newest funding adopted Pulnovo Medical’s current CE-MDR certification in Europe, marking a serious step ahead in increasing therapy choices for sufferers with pulmonary hypertension globally. It’s anticipated to speed up the corporate’s international enlargement by supporting worldwide scientific trials, regulatory approvals, indication enlargement, and commercialization.
Based in 2013 and led by Cynthia Chen, Chairwoman and Government Chair, Pulnovo Medical addresses a crucial unmet want in cardiovascular care by growing a first-in-class medical gadget primarily based on pulmonary artery denervation (PADN) core know-how. It was awarded US FDA Breakthrough System designation in 2021 and FDA Humanitarian Use System designation in 2023. Its catheter and generator acquired China NMPA Approval as a breakthrough gadget in late 2023, adopted by FDA clearance of the 9F sheath in 2024. In March 2025, the corporate obtained CE-MDR certification, marking a key milestone towards international commercialization.
FinSMEs
22/05/2025
